Search Results - xing+yang

5 Results

Sort By:

Radiolabeled Triazole Conjugated Ureas (YC-88)

Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein expressed on the surface of prostate tumors, particularly in castrate-resistant, advanced and metastatic disease. PSMA is also expressed in neovascular endothelium of most solid tumors, such as lung, colon, pancreatic, renal carcinoma and skin melanoma, but not in normal...

Published: 3/13/2025 | Inventor(s): Martin Pomper, Ronnie Mease, Ying Chen, Sangeeta Ray, Xing Yang

Keywords(s): Antagonists/Inhibitors, Cancers, Discovery/Research Tools, Disease Indication, Imaging Agent, Imaging and Sensing Systems, In Vivo Medical Imaging, Labels/Markers, Novel, Predicted Novelty, Research Reagent, Single, Small Molecules, Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Technology Classifications > Diagnostics > Diagnostic Imaging

Salicylic Acid-based Polymeric CEST Contrast Agents for Molecular Imaging of Prostate-specific Membrane Antigen

We have discovered that a salicylic acid (SA) analog when grafted on a polymeric platform is able to produce significantly enhanced contrast in MR images detectable through chemical exchange saturation transfer (CEST). That SA modified polymeric platform (SA PolyCEST), has been further modified with Glu-Lysine urea, an inhibitor of Prostate-specific...

Published: 3/13/2025 | Inventor(s): Xing Yang, Michael Mcmahon, Sangeeta Ray, Xiaolei Song, Martin Pomper

Keywords(s): Cancers, Disease Indication, Imaging Agent, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Magnetic Resonance Imaging (MRI), Prostate Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Medical Devices > Imaging, Technology Classifications > Medical Devices, Clinical and Disease Specializations > Oncology

New Scaffolds and Multifunctional Intermediates for Imaging PSMA

The prostate-specific membrane antigen (PSMA) is increasingly recognized as an important target for cancer imaging and therapy. Current PSMA inhibitors based on a urea scaffold have shown good results for imaging with positron emission tomography (PET) and single photon emission computed tomography (SPECT) in human subjects. The urea scaffold has...

Published: 3/13/2025 | Inventor(s): Martin Pomper, Ying Chen, Sangeeta Ray, Ronnie Mease, Xing Yang, Georgio Attardo

Keywords(s): Cancers, Disease Indication, Imaging Agent, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Positron Emission Tomography (PET), Prostate Cancer

Azole Heterocycles for MRI Contrast and pH Sensing

C12402: Novel Class of Organic MRI Contrast AgentsNovelty: Group of organic compounds as magnetic resonance imaging (MRI) contrast agents for detecting pH changes in vivo.Value Proposition: The most commonly used MRI contrast agents contain the metal gadolinium which been associated with Nephrogenic Systemic Fibrosis. Therefore, organic agents serve...

Published: 3/13/2025 | Inventor(s): Sangeeta Ray, Martin Pomper, Xing Yang, Xiaolei Song, Michael Mcmahon

Keywords(s): Imaging Agent, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Magnetic Resonance Imaging (MRI)

Category(s): Technology Classifications > Medical Devices > Imaging, Technology Classifications > Medical Devices

Salicylic Acid and Its Analogs for MRI Contrast

C12400: Salicylic Acid and its Analogs as MRI Contrast AgentsNovelty: New use of salicylic acid and its analogues as improved contrast agents for magnetic resonance imaging (MRI).Value Proposition: Currently used MRI contrast agents either have toxic effects or have certain sensitivity drawbacks, especially due to a small chemical shift difference between...

Published: 3/13/2025 | Inventor(s): Sangeeta Ray, Xing Yang, Martin Pomper, Xiaolei Song, Michael Mcmahon

Keywords(s): Imaging Agent, Imaging and Sensing Systems, Imaging Modality, In Vivo Medical Imaging, Magnetic Resonance Imaging (MRI), Non-novel, Predicted Novelty, Repurposed

Category(s): Technology Classifications > Medical Devices > Imaging, Technology Classifications > Medical Devices, Technology Classifications > Diagnostics > Diagnostic Imaging